Inhibition of nicotinic acetylcholine receptors by oligoarginine peptides and polyamine-related compounds
Frontiers in Pharmacology · 15.12.2023 · 14
DOI: 10.3389/fphar.2023.1327603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.12.2023. Verfasst von Lucy O Ojomoko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oligoarginine peptides, known mostly for their cell-penetrating properties, are also inhibitors of the nicotinic acetylcholine receptors (nAChRs). Since octa-arginine (R8) inhibits α9α10 nAChR and suppresses neuropathic pain, we checked if other polycationic compounds containing amino and/or guanidino groups could be effective and tested the activity of the disulfide-fixed “cyclo”R8, a series of biogenic polyamines (putrescine, spermidine, and spermine), C -methylated spermine analogs, agmatine and its analogs, as well as acylpolyamine argiotoxin-636 from spider venom. Their inhibitory potency on muscle-type, α7 and α9α10 nAChRs was determined using radioligand analysis, electrophysiology, and calcium imaging. “Cyclo”R8 showed similar activity to that of R8 against α9α10 nAChR (IC 50 ≈ 60 nM). Biogenic polyamines as well as agmatine and its analogs displayed low activity on muscle-type Torpedo californica , as well as α7 and α9α10 nAChRs, which increased with chain length, the most active being spermine and its C -methylated derivatives having IC 50 of about 30 μM against muscle-type T. californica nAChR. Argiotoxin-636, which contains a polyamine backbone and terminal guanidino group, also weakly inhibited T. californica nAChR (IC 50 ≈ 15 μM), but it revealed high potency against rat α9α10 nAChR (IC 50 ≈ 200 nM). We conclude that oligoarginines and similar polycationic compounds effectively inhibiting α9α10 nAChR may serve as a basis for the development of analgesics to reduce neuropathic pain.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
- Moscow Institute of Physics and Technology (State University), Moscow, Russia.
Zitieren
APA
Ojomoko, L. O., Kryukova, E. V., Egorova, N. S., Salikhov, A. I., Epifanova, L. A., Denisova, D. A., Khomutov, A. R., Sukhov, D. A., Vassilevski, A. A., Khomutov, M. A., Tsetlin, V. I., & Shelukhina, I. V. (2023). Inhibition of nicotinic acetylcholine receptors by oligoarginine peptides and polyamine-related compounds. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1327603
Vancouver
Ojomoko LO, Kryukova EV, Egorova NS, Salikhov AI, Epifanova LA, Denisova DA, et al. Inhibition of nicotinic acetylcholine receptors by oligoarginine peptides and polyamine-related compounds. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1327603
BibTeX
@article{Ojomoko2023,
author = {Ojomoko, Lucy O and Kryukova, Elena V and Egorova, Natalya S and Salikhov, Arthur I and Epifanova, Lyubov A and Denisova, Daria A and Khomutov, Alex R and Sukhov, Dmitry A and Vassilevski, Alexander A and Khomutov, Maxim A and Tsetlin, Victor I and Shelukhina, Irina V},
title = {Inhibition of nicotinic acetylcholine receptors by oligoarginine peptides and polyamine-related compounds},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1327603}
}
EUVIMED